explore -WSS

explore

author：knowledge 2025-09-06 20:45:58 - browse：55919

A screen at the New York Stock Exchange last November. Michael M. Santiago/Getty Images

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline.

The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.) It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030.

That matters because small molecules are more vulnerable to generic competition and the Medicare price negotiation introduced by the IRA. Suneet Varma, the commercial president of Pfizer’s oncology unit, said “this planned shift to biologics is expected to support the accelerated growth in both the top and bottom line,” referring to the revenue and profit lines of a balance sheet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Headspace, Meta partner to launch VR meditation app for Quest

WSS

Yancopoulos of Regeneron works to expand Dupixent success

Diabetes management: Digital health tools fall short, study says

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Steward Health Care expansion into Malta flopped

Biotech investment managers search for lucrative opportunities

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

entertainment

explore

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Medicare Advantage insurers pressure Biden for bigger payments

Moonlake's readout produced a cash windfall. Risks remain

This gene therapy has record $4.25 million price. It's saved children.

BioMarin wins approval for gene therapy to treat hemophilia A

How to bring more disabled researchers into academia

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Biotech investment managers search for lucrative opportunities

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Sen. Paul opposes bill to ban Chinese biotechs

entertainment

With psoriasis trial ahead, Alumis raises $259 million

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

First medicine developed to treat MASH expected to be approved soon

With Wegovy coverage, Medicare patients may face high costs

Cancer, immunology, HIV research ensnared in fetal tissue politics

The Readout: Amylyx, Alumis, and Lundbeck drug updates

leisure time

entertainment

hotspot

Wikipedia